RT Journal Article SR Electronic T1 Identification of Melanoma Antigens Using a Serological Proteome Approach (SERPA) JF Cancer Genomics - Proteomics JO Cancer Genomics Proteomics FD International Institute of Anticancer Research SP 17 OP 23 VO 7 IS 1 A1 AYAKO SUZUKI A1 AKIRA IIZUKA A1 MASARU KOMIYAMA A1 MASAKO TAKIKAWA A1 AKIKO KUME A1 SACHIKO TAI A1 CHIE OHSHITA A1 AYUMI KURUSU A1 YOUJI NAKAMURA A1 AKIFUMI YAMAMOTO A1 NAOYA YAMAZAKI A1 SHUSUKE YOSHIKAWA A1 YOSHIO KIYOHARA A1 YASUTO AKIYAMA YR 2010 UL http://cgp.iiarjournals.org/content/7/1/17.abstract AB Background: Melanoma is an intractable cancer with a poor prognosis and increasing prevalence worldwide. Specific biomarkers for early diagnosis have yet to be found. Materials and Methods: Serum samples from melanoma patients and healthy volunteers were utilized for identifying melanoma marker proteins using a serological proteome approach. Specifically, G361 cell protein spots separated by 2-dimensional gel electrophoresis and transferred to a membrane were incubated with patient sera, and positive spots that reacted with more than 5 serum samples were identified using time of flight mass spectrometry. Results: Only patient sera showed many spots reacted in G361 gels. A total of 13 positive spots were detected and 5 proteins were identified: eukaryotic elongation factor2 (EEF2), enolase1 (ENO1), aldolase A (ALDOA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and heterogeneous nuclear ribonucleoproteins (HNRNP) A2B1. The mRNAs of four proteins (EEF2, ENO1, ALDOA and HNRNPA2B1) were highly expressed in G361 cells compared with melanocytes. EEF2, ENO1 and ALDOA mRNAs were also frequently expressed in other melanoma cell lines. Conclusion: The autoantibody-based proteomic approach was effective for investigating melanoma biomarkers. This study might contribute to the development of a diagnostic device for the early detection of cancer. Copyright© 2010 International Institute of Anticaner Research (Dr. John G. Delinassios), All rights reserved